AbbVie’s telisotuzumab vedotin (Teliso-V) was recently granted FDA Breakthrough Designation for use in patients with advanced or metastatic EGFR wild-type non-squamous NSCLC whose cancer has advanced or progressed after being treated with platinum-based therapy. The designation is based on the Phase 2 LUMINOSITY Trial (Study M14-239). Teliso-V is an antibody-drug conjugate (ADC) targeting c-MET that is linked to monomethyl auriastatin E (MMAE) as a monotherapy in the second- or third-line setting. Currently, no therapies specifically target c-MET overexpressing NSCLC.
The treatment is being administered in two additional studies. In the Phase 1 Study (MN14-237), Teliso-V is being administered with osimertinib to patients with NSCLC with c-MET overexpression that have been previously treated. In the Phase 3 TeliMet NSCLC001 (Study M18-868) Trial, the drug is used as a monotherapy in NSCLC patients with c-MET overexpression that have been previously treated. Some of the data from these studies is expected to be presented at conferences this year.